DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2707ea/sweden_pharmaceuti) has announced the addition of the "Sweden Pharmaceuticals and Healthcare Report Q3 2011" report to their offering.
The Sweden Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Sweden's pharmaceuticals and healthcare industry.
While Sweden boasts one of the most admirable economies in the world, its pharmaceutical market is not considered as attractive as that of most of its Western European peers. This is mostly due to the country's modest population size, under 10mn people, as its per capita spending levels are comparable to those in major European markets. Risks to report forecasts are on the upside and the downside: the former in terms of higher public spending given the fast pace of economic recovery, with the latter based on pricing pressures should export economies falter, causing a Swedish economic slowdown.
Headline Expenditure Projections:
- Pharmaceuticals: SEK30.57bn (US$3.85bn) in 2010 to SEK31.12bn (US$4.17bn) in 2011; +1.8% in local currency terms and +8.4% in US dollar terms. Forecast up slightly from Q211 due to macroeconomic factors.
- Healthcare: SEK323.81bn (US$40.75bn) in 2010 to SEK336.87bn (US$45.14bn) in 2011; +4.0% in local currency terms and +10.8% in US dollar terms. Forecast up slightly from Q211 due to macroeconomic factors.
- Medical devices: SEK19.28bn (US$2.43bn) in 2010 to SEK20.07bn (US$2.69bn) in 2011; +4.1% in local currency terms and +10.8% in US dollar terms. Forecast up slightly from Q211 due to macroeconomic factors.
Business Environment Rating:
In this report Sweden remains ranked as the seventh most attractive market of the 10 Western European markets surveyed. The country scored an unchanged 61.4 out of 100, which remains below the regional average. While its strong emphasis on the regulatory environment is a draw, a major factor affecting the business environment for drugmakers is Sweden's small overall market size, which - combined with pressures on pharmaceutical spending - negatively affects the Industry Rewards score in particular.
Companies Mentioned:
- Meda
- Swedish Orphan Biovitrum
For more information visit http://www.researchandmarkets.com/research/2707ea/sweden_pharmaceuti